Cover Story
Conversation with The Cancer LetterRegulatory News
By Matthew Bin Han Ong and Paul Goldberg
When conducting a randomized clinical trial of a treatment regimen based on an immune checkpoint inhibitor, trial sponsors should include overall survival as an endpoint, FDA officials say.
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Lei Zheng named executive director of Mays Cancer Center
- Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence - NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready”
“All research now involves data science at some level.”